What was the market valuation of the US gene editing market in 2024?

The market valuation of the US gene editing market was $2500.0 Million in 2024. Read More

What is the projected market valuation for the US gene editing market by 2035?

The projected market valuation for the US gene editing market is $20000.0 Million by 2035. Read More

What is the expected CAGR for the US gene editing market during the forecast period 2025 - 2035?

The expected CAGR for the US gene editing market during the forecast period 2025 - 2035 is 20.81%. Read More

Which technology segment had the highest valuation in the US gene editing market in 2024?

In 2024, the CRISPR technology segment had the highest valuation at $1000.0 Million. Read More

What are the key applications driving the US gene editing market?

Key applications driving the US gene editing market include genetic engineering and clinical applications, with valuations of $1000.0 Million and $1500.0 Million respectively in 2024. Read More

Which method segment is expected to dominate the US gene editing market by 2035?

The In-Vivo method segment is expected to dominate the US gene editing market by 2035, with a projected valuation of $12000.0 Million. Read More

How did the valuation of the TALEN technology segment compare to others in 2024?

In 2024, the TALEN technology segment was valued at $600.0 Million, which was lower than the CRISPR segment but higher than ZFN, antisense, and others. Read More

Which companies are considered key players in the US gene editing market?

Key players in the US gene editing market include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Vertex Pharmaceuticals, Amgen, Bayer, and Novartis. Read More

What is the anticipated growth trend for the US gene editing market in the coming years?

The US gene editing market is anticipated to experience robust growth, with a projected increase in valuation from $2500.0 Million in 2024 to $20000.0 Million by 2035. Read More

US Gene Editing Market

Q: What are the primary end users in the US gene editing market?

Primary end users in the US gene editing market include biotechnology and pharmaceutical companies, contract research organizations (CROs), and academic & government research institutes. Read More

ID: MRFR/LS/11815-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Gene Editing Market Research Report: Size, Share, Trend Analysis By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Applications (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End Users (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic & Government Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Technology (USD Million)
  1. 4.1.1 CRISPR
  2. 4.1.2 TALEN
  3. 4.1.3 ZFN
  4. 4.1.4 antisense
  5. 4.1.5 others
2. 4.2 Chemicals and Materials, BY Application (USD Million)
  1. 4.2.1 genetic engineering
  2. 4.2.2 clinical application
3. 4.3 Chemicals and Materials, BY Method (USD Million)
  1. 4.3.1 Ex-vivo
  2. 4.3.2 In-Vivo
4. 4.4 Chemicals and Materials, BY End User (USD Million)
  1. 4.4.1 biotechnology and pharmaceutical companies
  2. 4.4.2 contract research organizations (CROs)
  3. 4.4.3 academic & government research institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 CRISPR Therapeutics (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Editas Medicine (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Intellia Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Vertex Pharmaceuticals (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bayer (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novartis (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY METHOD
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY METHOD, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY METHOD, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Technology (USD Million, 2025-2035)

CRISPR
TALEN
ZFN
antisense
others

Chemicals and Materials By Application (USD Million, 2025-2035)

genetic engineering
clinical application

Chemicals and Materials By Method (USD Million, 2025-2035)

Ex-vivo
In-Vivo

Chemicals and Materials By End User (USD Million, 2025-2035)

biotechnology and pharmaceutical companies
contract research organizations (CROs)
academic & government research institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”